Genmab starts Phase I/II HuMax-CD38 trial for Myeloma

Genmab (GEN.CO) started a Phase I/II safety and dose finding study of its human antibody HuMax-CD38 for the treatment of multiple myeloma, a plasma cell disorder.

The study will include up to 122 patients who are relapsed or resistant to at least two different prior treatments. HuMax-CD38 is an antibody that targets the CD38 molecule on the surface of multiple myeloma tumour cells.